Zydus Cadila said ZYIL1 will bridge a critical unmet healthcare need in several inflammatory diseases including COVID-19 Drug firm Zydus Cadila on Tuesday said it has filed the investigational new drug (IND) application for ZYIL1, positioned for management of critically ill COVID-19 patients. “Following up on its initiatives to fight COVID-19 with diagnostics, vaccines and therapeutics, the …